Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14α-demethylase (CYP51)

European Journal of Medicinal Chemistry

Volumn 42, Issue 9, 2007, Pages 1226-1233

  Sun, Qing Yan ^a   Xu, Jian Ming ^a   Cao, Yong Bing ^a   Zhang, Wan Nian ^a   Wu, Qiu Ye ^a   Zhang, Da Zhi ^a   Zhang, Jun ^a   Zhao, Hui Qing ^a   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antifungal activity; CYP51; Synthesis; Triazole

Indexed keywords

1 (1H 1,2,4 TRIAZOL 1 YL) 2 (2,4 DIFLUOROPHENYL) 3 [4 (2 FLUORO 4 AMINOPHENYL)PIPERAZIN 1 YL]PROPAN 2 OL; 1 (1H 1,2,4 TRIAZOL 1 YL) 2 (2,4 DIFLUOROPHENYL) 3 [4 (2 FLUORO 4 NITROPHENYL)PIPERAZIN 1 YL]PROPAN 2 OL; 2 BROMO N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; 2 CHLORO N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; 2,4 DICHLORO N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; 3 BROMO N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; 3 CHLORO N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; 4 BUTYL N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; 4 CHLORO N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; 4 TERT BUTYL N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; CYTOCHROME P450 INHIBITOR; FLUCONAZOLE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 2 FLUOROBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 2 METHOXYBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 2 METHYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 2,4 DIMETHYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 3 METHOXYBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 3 METHYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 3 TRIFLUOROMETHYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 3,4 DIMETHYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 4 ETHYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 4 FLUOROBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 4 ISOPROPYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 4 METHOXYBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 4 METHYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 4 PENTYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 4 PROPYLBENZAMIDE; N [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 3 [1H 1,2,4]TRIAZOL 1 YLPROPYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL]BENZAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; FONSECAEA; IN VITRO STUDY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MICROSPORUM GYPSEUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, INFRARED; TRIAZOLES;

EID: 34547760374     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2007.01.006     Document Type: Article

References (13)

1. Fridkin S.K., and Jarvis W.R. Clin. Microbiol. Rev. 9 (1996) 499-511
2. Wingard J.R., and Leather H. Biol. Blood Marrow Transplant. 10 (2004) 73-90
3. Kale P., and Johnson L.B. Drugs Today 41 (2005) 91-105
4. Chandrasekar P.H., and Manavathu E. Drugs Today 37 (2001) 135-148
5. Chen A., and Sobel J.D. Expert Opin. Emerg. Drugs 10 (2005) 21-33
6. Sundriyal S., Sharma R.K., and Jain R. Curr. Med. Chem. 13 (2006) 1321-1335
7. Ji H., Zhang W., Zhou Y., Zhang M., Zhu J., Song Y., and Lu J. J. Med. Chem. 43 (2000) 2493-2505
8. Lewis D.F., Wiseman A., and Tarbit M.H. J. Enzym. Inhib. 14 (1999) 175-192
9. K. Richardson, USP: 4404216, 1983.
10. Yang J., Liu L., Wang X., Lu J., Sun C., Zhang H., Zhou Y., and Zhang Z. Yiyao Gongye 5 (1984) 1-4
11. D.K. Hutchinson, M.R. Barbachyn, S.J. Brickner, R.B. Gammill, M.V. Patel, USP: 880432, 1996.
12. Sun Q., Liu C., Wu Q., Zhang D., Cao Y., Jiang Y., and Zhao H. Zhongguo Yaowu Huaxue Zazhi 14 (2004) 14-18
13. National Committee for Clinical Laboratory Standards. Approved standard, Document M27-A2. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts (2002), National Committee for Clinical Laboratory Standards, Wayne, PA